Telix Pharmaceuticals revenue and financials
In the fiscal year ended December 2025, Telix Pharmaceuticals reported revenue of $803.79M (+55.61% year over year). The net loss was $7.13M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +55.61%
- 2025 vs 2024
- Net margin
- -0.9%
- 2024: 6.5%
How Telix Pharmaceuticals is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 188.7% a year on average over the last 5 years
Compound annual growth rate: from $4.01M in 2020 to $803.79M in 2025.
Revenue has grown for 7 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin rose from −46.3% to 2.4%
Operating income over revenue, 2022 → 2025: 48.7 percentage points.
Less cash than profit: free cash flow equal to -54% of net income
Totals for fiscal years 2023–2025: free cash flow -$16.65M, net income $30.77M.
Shares outstanding up 31.3% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 2 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 804 | 517 | 333 | 109 | 5.5 | 4.0 | 2.4 | 0.1 | — | — |
| Cost of revenue | 422 | 197 | 130 | 44.4 | 1.8 | 1.6 | 1.8 | — | — | — |
| Gross profit | 382 | 319 | 203 | 64.7 | 3.7 | 2.5 | 0.7 | 0.1 | — | — |
| Selling, general and administrative | 193 | 136 | 83.1 | 59.3 | 34.1 | 18.8 | 11.1 | 6.4 | 2.8 | 0.0 |
| Research and development | 171 | 128 | 85.3 | 55.2 | 24.8 | 17.8 | 14.9 | 13.2 | 2.3 | 0.0 |
| Operating income | 19.3 | 55.9 | 35.0 | -50.5 | -59.0 | -37.9 | -28.3 | -19.5 | -5.1 | -0.0 |
| EBIT | 19.3 | 55.9 | 35.0 | -50.5 | -59.0 | -37.9 | -28.3 | -19.5 | -5.1 | -0.0 |
| EBITDA | 32.5 | 59.6 | 38.2 | -47.4 | -55.7 | -34.6 | -25.5 | -19.5 | -5.1 | — |
| Interest expense | 13.8 | 4.8 | 0.5 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -5.3 | 37.9 | 2.6 | -67.2 | -58.4 | -36.9 | -21.9 | -11.1 | -5.0 | -0.0 |
| Income tax | 1.9 | 4.2 | -1.6 | 3.7 | 0.0 | -2.3 | -2.3 | -1.3 | — | — |
| Net income | -7.1 | 33.7 | 4.2 | -70.9 | -58.5 | -34.5 | -19.6 | -9.7 | -5.0 | -0.0 |
| Net income to common shareholders | -7.1 | 33.7 | 4.2 | -70.9 | -58.5 | -34.5 | -19.6 | -9.7 | -5.0 | -0.0 |
| Basic EPS | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 | -0.13 | -0.08 | -0.05 | -0.04 | — |
| Diluted EPS | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 | -0.13 | -0.08 | -0.05 | -0.04 | — |
| Average shares (basic) | 338 | 331 | 319 | 311 | 282 | 257 | 233 | 202 | 128 | — |
| Average shares (diluted) | 338 | 345 | 324 | 311 | 282 | 257 | 233 | 202 | 128 | — |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 477 | 413 | 390 | 277 | 240 | 192 | 147 | 92.5 | 16.6 | 3.4 |
| Cost of revenue | 246 | 221 | 201 | 106 | 90.8 | 76.3 | 57.3 | 37.1 | 7.3 | 1.2 |
| Gross profit | 232 | 192 | 190 | 171 | 149 | 116 | 89.7 | 55.4 | 9.3 | 2.2 |
| Selling, general and administrative | 107 | 95.9 | 96.7 | 71.7 | 63.8 | 47.6 | 36.3 | 25.6 | 34.0 | 21.7 |
| Research and development | 124 | 89.7 | 81.6 | 72.5 | 55.4 | 54.4 | 32.4 | 38.2 | 17.1 | 14.9 |
| Operating income | 46.4 | 8.0 | 10.4 | 26.2 | 29.7 | 14.2 | 20.6 | -7.2 | -43.7 | -36.3 |
| EBIT | 46.4 | 8.0 | 10.4 | 26.2 | 29.7 | 14.2 | 20.6 | -7.2 | -43.7 | -36.3 |
| EBITDA | 57.3 | 14.2 | 20.0 | 27.5 | 32.2 | 15.7 | 22.7 | -6.0 | -41.9 | -34.9 |
| Interest expense | 7.4 | 7.6 | 6.2 | 4.5 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 |
| Pre-tax income | 29.2 | -0.4 | -4.8 | 15.0 | 22.9 | 10.5 | -8.2 | -19.0 | -48.7 | -34.9 |
| Income tax | -9.1 | 4.4 | -2.5 | 0.9 | 3.3 | -2.8 | 1.3 | 3.6 | 0.1 | -0.0 |
| Net income | 38.3 | -4.8 | -2.3 | 14.1 | 19.6 | 13.3 | -9.5 | -22.6 | -48.8 | -34.9 |
| Net income to common shareholders | 38.3 | -4.8 | -2.3 | 14.1 | 19.6 | 13.3 | -9.5 | -22.6 | -48.8 | -34.9 |
| Basic EPS | 0.11 | -0.01 | -0.01 | 0.04 | 0.06 | 0.04 | -0.03 | -0.07 | -0.16 | -0.12 |
| Diluted EPS | 0.11 | -0.01 | -0.01 | 0.04 | 0.06 | 0.04 | -0.03 | -0.07 | -0.16 | -0.12 |
| Average shares (basic) | 339 | 339 | 331 | 335 | 328 | 321 | 318 | 314 | 307 | 283 |
| Average shares (diluted) | 357 | 339 | 331 | 351 | 339 | 330 | 318 | 314 | 307 | 283 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,164 | 940 | 277 | 174 | 79.7 | 121 | 72.0 | 54.1 | 39.9 |
| Current assets | 330 | 570 | 159 | 118 | 34.5 | 72.0 | 41.2 | 25.3 | 38.7 |
| Cash and equivalents | 142 | 440 | 84.3 | 79.3 | 16.0 | 60.0 | 31.3 | 18.2 | 38.0 |
| Receivables | 138 | 99.7 | 49.3 | 31.3 | 15.1 | 10.9 | 9.1 | 6.3 | 0.4 |
| Inventory | 37.1 | 23.6 | 12.7 | 5.8 | 2.5 | 0.5 | 0.4 | 0.5 | — |
| Net property, plant and equipment | 116 | 33.6 | 20.9 | 12.8 | 4.6 | 3.7 | 1.3 | 0.2 | 0.0 |
| Goodwill | 199 | 66.6 | — | 3.8 | 3.0 | 3.2 | 3.0 | 2.2 | 0.3 |
| Other intangible assets | 394 | 191 | 75.1 | 36.4 | 37.5 | 42.3 | 26.5 | 25.6 | 0.9 |
| Long-term investments | 3.7 | 3.8 | — | — | — | — | — | — | — |
| Current liabilities | 232 | 205 | 111 | 58.3 | 27.6 | 15.4 | 7.5 | 5.8 | 1.1 |
| Accounts payable | 71.7 | 42.2 | 54.3 | 11.4 | 8.6 | 4.5 | 4.9 | 2.3 | 0.2 |
| Long-term debt | 392 | 342 | 5.9 | 2.3 | — | 0.1 | 0.2 | 0.4 | — |
| Total debt | 467 | 360 | 12.3 | 7.1 | 1.8 | 1.7 | 1.5 | 1.2 | — |
| Total liabilities | 749 | 587 | 175 | 119 | 78.2 | 60.6 | 22.8 | 16.8 | 1.4 |
| Total equity (incl. minority) | 415 | 353 | 103 | 54.5 | 1.6 | 60.8 | 49.2 | 37.3 | 38.5 |
| Retained earnings | -155 | -153 | -187 | -186 | -126 | -71.5 | -33.8 | -14.2 | -5.0 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,362 | 1,164 | 1,190 | 940 | 498 | 277 | 207 | 174 | 149 | 79.8 |
| Current assets | 488 | 330 | 398 | 570 | 170 | 158 | 146 | 118 | 103 | 34.6 |
| Cash and equivalents | 252 | 142 | 207 | 440 | 79.3 | 84.0 | 87.7 | 79.1 | 84.5 | 16.0 |
| Receivables | 170 | 138 | 130 | 99.7 | 64.9 | 54.2 | 42.9 | 31.2 | 11.7 | 15.2 |
| Inventory | 39.0 | 37.1 | 35.2 | 23.6 | 20.6 | 11.8 | 8.4 | 5.8 | 4.5 | 2.5 |
| Net property, plant and equipment | 130 | 116 | 74.2 | 33.6 | 25.5 | 20.8 | 15.4 | 12.8 | 5.8 | 4.6 |
| Goodwill | 198 | 199 | 186 | 66.6 | 78.6 | 3.3 | 3.7 | 3.8 | 2.8 | 3.0 |
| Other intangible assets | 387 | 394 | 398 | 191 | 188 | 71.4 | 35.5 | 36.3 | 36.9 | 37.5 |
| Long-term investments | 40.4 | 3.7 | 4.1 | 3.8 | 7.0 | 8.4 | — | — | — | — |
| Current liabilities | 242 | 232 | 299 | 205 | 172 | 113 | 94.9 | 58.1 | 32.1 | 27.6 |
| Accounts payable | 169 | 71.7 | 51.7 | 42.2 | 14.9 | 22.4 | 22.6 | 11.4 | 7.3 | 8.6 |
| Long-term debt | 505 | 392 | 371 | 342 | 6.6 | 5.6 | 3.7 | 2.3 | — | — |
| Total debt | 580 | 467 | 418 | 360 | 14.8 | 11.9 | 8.7 | 7.1 | 1.8 | 1.8 |
| Total liabilities | 874 | 749 | 768 | 587 | 228 | 175 | 156 | 119 | 76.2 | 78.3 |
| Total equity (incl. minority) | 488 | 415 | 422 | 353 | 270 | 102 | 50.6 | 54.4 | 72.6 | 1.6 |
| Retained earnings | -111 | -155 | -151 | -153 | -156 | -180 | -190 | -185 | -168 | -126 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -17.3 | 27.5 | 14.3 | -43.6 | -43.1 | 1.5 | -16.4 | -14.6 | -4.7 |
| Depreciation and amortization | 20.9 | 5.3 | 4.2 | 3.7 | 3.8 | 3.8 | 3.0 | 0.0 | 0.0 |
| Capital expenditure | -25.7 | -9.1 | -6.3 | -4.8 | -1.0 | -0.2 | -0.3 | — | -0.0 |
| Investing cash flow | -286 | -86.7 | -16.8 | -11.6 | -2.0 | -0.8 | -0.3 | -1.9 | -0.0 |
| Financing cash flow | -3.7 | 417 | 7.1 | 119 | 2.1 | 26.2 | 30.0 | -0.6 | 42.7 |
| Share repurchases | — | — | — | -7.8 | — | — | — | — | — |
| Debt issued | 0.5 | 428 | 4.2 | 2.1 | — | — | — | — | — |
| Debt repaid | -6.1 | -2.1 | -1.3 | -0.9 | -0.7 | -0.7 | -0.8 | -0.6 | -0.6 |
| Effect of exchange rates | 8.8 | -1.9 | 1.0 | 0.2 | 2.4 | -1.3 | -0.1 | 0.9 | — |
| Net change in cash | -298 | 356 | 5.5 | 64.2 | -40.6 | 25.7 | 13.2 | -16.2 | 38.0 |
| Free cash flow | -43.0 | 18.4 | 8.0 | -48.3 | -44.1 | — | — | — | — |
| Levered free cash flow | -36.7 | 53.7 | 41.3 | -20.9 | -27.1 | -12.7 | -14.9 | -14.0 | — |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 23.0 | -35.0 | 17.7 | 4.2 | 23.3 | 7.2 | 8.8 | -2.5 | -41.5 | -22.3 |
| Depreciation and amortization | 11.0 | 11.4 | 9.6 | 2.8 | 2.4 | 2.4 | 2.1 | 1.8 | 1.9 | 1.9 |
| Capital expenditure | -14.5 | -19.0 | -6.7 | -6.1 | -3.1 | -4.5 | -2.0 | -3.2 | -1.6 | -0.7 |
| Investing cash flow | -33.7 | -27.1 | -259 | -56.3 | -30.4 | -15.4 | -1.9 | -3.8 | -7.8 | -1.4 |
| Financing cash flow | 118 | -0.8 | -2.9 | 415 | 1.4 | 3.7 | 3.1 | 2.6 | 118 | 1.8 |
| Debt issued | 587 | 0.5 | — | 426 | 1.8 | 2.2 | 1.7 | 2.0 | — | — |
| Debt repaid | -470 | -2.5 | -3.6 | -1.3 | -0.8 | -1.0 | -0.5 | -0.6 | -0.3 | -0.3 |
| Effect of exchange rates | 2.3 | -2.4 | 11.2 | -2.3 | 0.4 | -1.4 | 0.2 | -0.4 | 0.7 | 1.8 |
| Net change in cash | 110 | -65.3 | -233 | 361 | -5.3 | -5.8 | 10.2 | -4.3 | 69.3 | -20.1 |
| Free cash flow | 8.6 | -54.1 | 11.1 | -1.9 | 20.3 | 2.7 | 6.8 | -5.7 | -43.1 | -23.0 |
| Levered free cash flow | -0.9 | -57.5 | 25.0 | -5.6 | 59.3 | 10.9 | 31.2 | 4.1 | -25.3 | -14.3 |
Financial statements of similar companies
Companies in the group: same industry, similar size
